Paratek Appoints New Vice President
BOSTON-Paratek Pharmaceuticals, Inc., has appointed S. Ken Tanaka, Ph.D, as vice president of research and development. Tanaka's primary responsibilities with Paratek will be to oversee the company's innovative tetracycline and MAR (Multiple Antibiotic Resistance) programs, and will ensure new anti-infective products that address the worldwide problem of bacterial resistance.
Tanaka has 20 years of pharmaceutical industry experience in drug discovery, evaluation, and clinical, regulatory, and market development. His work has focused on oral, parenteral, and aerosolized antibacterial and antifungal drugs for E.R. Squibb and Sons, Inc., (now Bristol Myers-Squibb), Schwarz-Pharma, Abbott Laboratories, and PathoGenesis Corporation.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
